Have a feature idea you'd love to see implemented?
Let us know!
HAE Haemonetics Corp
Price (delayed)
$85.43
Market cap
$4.29B
P/E Ratio
35.16
Dividend/share
N/A
EPS
$2.43
Enterprise value
$5.22B
Haemonetics is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of
Highlights
The price to earnings (P/E) is 36% lower than the 5-year quarterly average of 55.3
The company's gross profit rose by 10% YoY and by 2.4% QoQ
HAE's net income is up by 8% since the previous quarter but it is down by 3.5% year-on-year
The company's EPS rose by 8% QoQ but it fell by 4% YoY
The debt has soared by 61% year-on-year
The company's quick ratio fell by 11% QoQ and by 6% YoY
Key stats
What are the main financial stats of HAE
Market
Valuations
Earnings
Shares outstanding
50.22M
Market cap
$4.29B
Enterprise value
$5.22B
Price to earnings (P/E)
35.16
Price to book (P/B)
4.97
Price to sales (P/S)
3.19
EV/EBIT
31.17
EV/EBITDA
18.84
EV/Sales
3.83
Revenue
$1.36B
EBIT
$167.37M
EBITDA
$276.9M
Free cash flow
$52.56M
Per share
Balance sheet
Liquidity
EPS
$2.43
Free cash flow per share
$1.03
Book value per share
$17.17
Revenue per share
$26.74
TBVPS
$27.92
Total assets
$2.53B
Total liabilities
$1.65B
Debt
$1.22B
Equity
$878.85M
Working capital
$681.96M
Debt to equity
1.39
Current ratio
3.49
Quick ratio
1.87
Net debt/EBITDA
3.34
Margins
Efficiency
Dividend
EBITDA margin
20.3%
Gross margin
52.6%
Net margin
9.1%
Operating margin
12.3%
Return on assets
5.2%
Return on equity
13.4%
Return on invested capital
9.2%
Return on capital employed
7.4%
Return on sales
12.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
HAE stock price
How has the Haemonetics stock price performed over time
Intraday
0.6%
1 week
-5.86%
1 month
14.1%
1 year
3.61%
YTD
-0.09%
QTD
6.28%
Financial performance
How have Haemonetics's revenue and profit performed over time
Revenue
$1.36B
Gross profit
$716.13M
Operating income
$167.37M
Net income
$123.81M
Gross margin
52.6%
Net margin
9.1%
The net margin is down by 13% year-on-year but it is up by 6% since the previous quarter
The operating income is up by 11% since the previous quarter
The company's gross profit rose by 10% YoY and by 2.4% QoQ
The revenue rose by 10% YoY and by 2% QoQ
Growth
What is Haemonetics's growth rate over time
Valuation
What is Haemonetics stock price valuation
P/E
35.16
P/B
4.97
P/S
3.19
EV/EBIT
31.17
EV/EBITDA
18.84
EV/Sales
3.83
The price to earnings (P/E) is 36% lower than the 5-year quarterly average of 55.3
The company's EPS rose by 8% QoQ but it fell by 4% YoY
The price to book (P/B) is 14% lower than the 5-year quarterly average of 5.8 but 8% higher than the last 4 quarters average of 4.6
The equity has declined by 2.9% since the previous quarter
The stock's P/S is 22% less than its 5-year quarterly average of 4.1
The revenue rose by 10% YoY and by 2% QoQ
Efficiency
How efficient is Haemonetics business performance
The company's return on invested capital fell by 21% YoY but it rose by 2.2% QoQ
The company's return on assets fell by 21% YoY
HAE's return on equity is down by 12% year-on-year but it is up by 8% since the previous quarter
The company's return on sales fell by 9% YoY but it rose by 9% QoQ
Dividends
What is HAE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for HAE.
Financial health
How did Haemonetics financials performed over time
The total assets is 53% more than the total liabilities
The total liabilities has grown by 47% YoY
The total assets has grown by 26% YoY
The debt is 39% greater than the equity
The debt to equity has soared by 64% YoY and by 3% from the previous quarter
The debt has soared by 61% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.